• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by ATAI Life Sciences N.V.

    7/1/25 9:30:12 PM ET
    $ATAI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ATAI alert in real time by email
    DEFA14A 1 ef20051488_defa14a.htm DEFA14A

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, DC 20549



    SCHEDULE 14A
    Proxy Statement Pursuant to Section 14(a) of the
    Securities Exchange Act of 1934


    Filed by the Registrant ☒

    Filed by a party other than the Registrant ☐

    Check the appropriate box:

    ☐
    Preliminary Proxy Statement

    ☐
    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

    ☐
    Definitive Proxy Statement

    ☐
    Definitive Additional Materials

    ☒
    Soliciting Material under § 240.14a-12

    ATAI LIFE SCIENCES N.V.
    (Name of Registrant as Specified In Its Charter)

    (Name of Person(s) Filing Proxy Statement, if Other Than the Registrant)

    Payment of Filing Fee (Check all boxes that apply):

    ☒
    No fee required

    ☐
    Fee paid previously with preliminary materials

    ☐
    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11



    Christian Angermayer

    Founder bei Apeiron Investment Group

    Today is another great day for atai Life Sciences. We just announced outstanding Phase 2b data for BPL-003 (5-MeO-DMT).

    But that’s not all. Core shareholders, including myself, demonstrated our conviction in atai’s mission and potential by investing an additional $50 million alongside top-tier biotech funds.

    This adds to the $90 million raised earlier this year, extending our runway into the second half of 2027 and enabling full-speed preparations for the Phase 3 trials of BPL-003.

    I’ll be publishing a blog post soon – stay tuned.

    https://lnkd.in/ezNP6Pta

    Forward-looking Statements

    This communication contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. atai intends such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). The words “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “anticipate,” “initiate,” “could,” “would,” “project,” “plan,” “potentially,” “preliminary,” “likely,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements include express or implied statements relating to, among other things: expectations regarding the closing of the acquisition of Beckley Psytech Limited (the “Proposed Transaction”), including timing and approvals; expectations regarding operations of the combined company, including strategic value of the clinical development programs for patients and shareholders as well as expectations regarding financial synergies; timing and results of Beckley Psytech’s BPL-003 Phase 2b trial and related data readouts (results of such Phase 2b trial have now been made available, as previously reported by atai); expectations regarding Beckley Psytech’s other clinical assets, including ELE-101; expectations regarding the concurrent private placement, including related closing conditions; atai’s business strategy and plans; and the potential, success, cost and timing of development of atai’s product candidates, and the product candidates of those companies atai invests in.

    Forward-looking statements are neither promises nor guarantees, but involve known and unknown risks and uncertainties that could cause actual results to differ materially from those projected, including, without limitation, (i) the Proposed Transaction may not be completed in a timely manner or at all, including the risk that any required shareholder approvals are not obtained; (ii) the failure to realize the anticipated benefits of the Proposed Transaction; (iii) the possibility that any or all of the various conditions to the consummation of the Proposed Transaction may not be satisfied or waived; (iv) the occurrence of any event, change or other circumstance that could give rise to the termination of the share purchase agreement; and (v) the effect of the announcement or pendency of the Proposed Transaction on atai’s ability to retain and hire key personnel, or its operating results and business generally and other important factors described in the section titled “Risk Factors” in atai’s most recent Annual Report on Form 10-K filed with the SEC, as such factors may be updated from time to time in atai’s other filings with the SEC. atai disclaims any obligation or undertaking to update or revise any forward-looking statements contained in this communication, other than to the extent required by applicable law.


    No Offer or Solicitation

    This communication is for information purposes only and is not intended to and does not constitute, or form part of, an offer, invitation or the solicitation of an offer or invitation to purchase, otherwise acquire, subscribe for, sell or otherwise dispose of any securities, or the solicitation of any vote or approval in any jurisdiction, pursuant to the Proposed Transaction or otherwise, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law.

    Additional Information and Where to Find It

    This communication is being made in respect of the Proposed Transactions. In connection with the Proposed Transaction, a registration statement on Form S-4 will be filed (the “Registration Statement”) which will include a proxy statement of the Company (the “Proxy Statement”), as well as other relevant documents regarding the Proposed Transaction. This communication is not a substitute for the Registration Statement, the Proxy Statement or any other document which the Company may file with the SEC. INVESTORS ARE URGED TO READ IN THEIR ENTIRETY THE REGISTRATION STATEMENT, INCLUDING THE PROXY STATEMENT REGARDING THE PROPOSED TRANSACTION, WHEN IT BECOMES AVAILABLE AND ANY OTHER RELEVANT DOCUMENTS FILED WITH THE SEC, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THOSE DOCUMENTS, BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION.

    A free copy of the Registration Statement, including the Proxy Statement, as well as other filings containing information about the Company, when such documents become available, may be obtained at the SEC’s website (http://www.sec.gov).

    Participants in the Solicitation

    The Company and its directors and executive officers may be deemed to be participants in the solicitation of proxies from its shareholders in respect of the proposed transactions contemplated by the Registration Statement, including the Proxy Statement. Information regarding the persons who are, under the rules of the SEC, participants in the solicitation of the shareholders of the Company in connection with the proposed transactions, including a description of their direct or indirect interests, by security holdings or otherwise, will be set forth in the Registration Statement, including the Proxy Statement, when it is filed with the SEC. Information regarding the Company’s directors and executive officers is contained in its Annual Report on Form 10-K for the year ended December 31, 2024 and its proxy statement on Schedule 14A, dated April 21, 2025, which are filed with the SEC.



    Get the next $ATAI alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $ATAI

    DatePrice TargetRatingAnalyst
    4/4/2025Buy
    Berenberg
    11/18/2024$15.00 → $10.00Buy
    H.C. Wainwright
    4/3/2024$6.00Hold → Buy
    Maxim Group
    11/1/2022$18.00Buy
    Loop Capital
    11/30/2021$25.00Buy
    Maxim Group
    11/22/2021$40.00 → $50.00Buy
    HC Wainwright & Co.
    11/16/2021$25.00 → $24.00Outperform
    Credit Suisse
    11/16/2021$19.00 → $17.00Sector Perform
    RBC Capital
    More analyst ratings

    $ATAI
    SEC Filings

    See more
    • SEC Form DEFA14A filed by ATAI Life Sciences N.V.

      DEFA14A - ATAI Life Sciences N.V. (0001840904) (Filer)

      7/1/25 9:30:39 PM ET
      $ATAI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by ATAI Life Sciences N.V.

      DEFA14A - ATAI Life Sciences N.V. (0001840904) (Filer)

      7/1/25 9:30:12 PM ET
      $ATAI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ATAI Life Sciences N.V. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

      8-K - ATAI Life Sciences N.V. (0001840904) (Filer)

      7/1/25 7:16:59 AM ET
      $ATAI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ATAI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Hoffman John Francis

      4 - ATAI Life Sciences N.V. (0001840904) (Issuer)

      6/27/25 5:31:24 PM ET
      $ATAI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Johnson Sabrina Martucci

      4 - ATAI Life Sciences N.V. (0001840904) (Issuer)

      6/27/25 5:31:27 PM ET
      $ATAI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Kalali Amir H

      4 - ATAI Life Sciences N.V. (0001840904) (Issuer)

      6/27/25 5:31:28 PM ET
      $ATAI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ATAI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Apeiron Investment Group Ltd. bought $2,520,000 worth of shares (1,800,000 units at $1.40) (SEC Form 4)

      4 - ATAI Life Sciences N.V. (0001840904) (Issuer)

      3/24/25 5:00:18 PM ET
      $ATAI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Apeiron Investment Group Ltd. bought $22,755,008 worth of shares (10,835,718 units at $2.10) (SEC Form 4)

      4 - ATAI Life Sciences N.V. (0001840904) (Issuer)

      2/19/25 6:00:05 PM ET
      $ATAI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Brand Florian bought $23,120 worth of shares (20,000 units at $1.16), increasing direct ownership by 18% to 130,000 units (SEC Form 4)

      4 - ATAI Life Sciences N.V. (0001840904) (Issuer)

      11/20/23 9:17:41 AM ET
      $ATAI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ATAI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Berenberg initiated coverage on atai Life Sciences N.V.

      Berenberg initiated coverage of atai Life Sciences N.V. with a rating of Buy

      4/4/25 8:27:07 AM ET
      $ATAI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • H.C. Wainwright reiterated coverage on atai Life Sciences N.V. with a new price target

      H.C. Wainwright reiterated coverage of atai Life Sciences N.V. with a rating of Buy and set a new price target of $10.00 from $15.00 previously

      11/18/24 11:31:29 AM ET
      $ATAI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • atai Life Sciences N.V. upgraded by Maxim Group with a new price target

      Maxim Group upgraded atai Life Sciences N.V. from Hold to Buy and set a new price target of $6.00

      4/3/24 8:14:20 AM ET
      $ATAI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ATAI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • atai Life Sciences Announces $50 Million Private Placement Financing

      NEW YORK and AMSTERDAM, July 01, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ:ATAI) ("atai"), a clinical-stage biopharmaceutical company on a mission to develop highly effective mental health treatments to transform patient outcomes, today announced it had entered into subscription agreements relating to the purchase of 18,264,840 ordinary shares of atai with a nominal value of €0.10 per share ("Common Shares") and pre-funded warrant to purchase 4,566,210 Common Shares (the "Pre-Funded Warrant"). The financing is expected to result in gross proceeds of approximately $50 million, before deducting placement agents' fees and other expenses. The net proceeds from the financing are expec

      7/1/25 6:05:00 AM ET
      $ATAI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • atai Life Sciences and Beckley Psytech Announce Positive Topline Results from the Phase 2b Study of BPL-003 in Patients with Treatment-Resistant Depression

      Study met its primary and all key secondary endpoints, and BPL-003 demonstrated rapid, robust and durable antidepressant effects with a single doseBoth 8 mg and 12 mg single doses of BPL-003 showed statistically significant and clinically meaningful reductions in depressive symptoms at all time points of the study compared to a 0.3 mg low-dose active control out to Week 8BPL-003 was generally well-tolerated at all doses, with 99% of treatment-emergent adverse events being mild or moderate, and no drug-related serious adverse events or suicide-related safety signalsMajority of patients deemed ready for discharge at the 90 minutes post-dose assessment, which suggests BPL-003 could fit within t

      7/1/25 6:00:00 AM ET
      $ATAI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • atai Life Sciences and Beckley Psytech to Combine Creating a Global Leader in Psychedelic Mental Health Therapies

      Strategic combination establishes a market-leading mental health company with a pipeline that includes potentially transformative, rapid-acting psychedelic assets differentiated by their convenient route of administration and short time-in-clinicCombined company will operate under the name atai Beckley with a joint leadership team and Board that leverage the deep psychedelic, drug development and CNS expertise within both organizationsTopline data from the Phase 2b study of BPL-003 in patients with treatment-resistant depression (TRD) is expected in mid-2025 - the largest controlled trial of mebufotenin (5-MeO-DMT) and the first and only controlled trial to investigate mebufotenin in the U.S

      6/2/25 6:00:00 AM ET
      $ATAI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ATAI
    Leadership Updates

    Live Leadership Updates

    See more
    • atai Life Sciences Announces Key Leadership Appointments as it Advances its Pipeline of Novel Psychedelic Therapeutics for Mental Health

      - Srinivas Rao M.D., Ph.D. succeeds as sole Chief Executive Officer- Kevin Craig, M.D. promoted to Chief Medical Officer- Glenn Short, Ph.D. promoted to Chief Scientific Officer- Gerd Kochendoerfer, Ph.D. joins as Chief Operating Officer NEW YORK and BERLIN, Jan. 10, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ:ATAI) ("atai" or "Company"), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced key leadership appointments to advance its goal of delivering novel mental health therapeutics. Srinivas Rao M.D., Ph.D., has assumed the role of sole Chief Executive Officer (CEO), joined by the promotions of Kevin Craig, M.D.

      1/10/25 7:00:00 AM ET
      $ATAI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • atai Life Sciences Strengthens Board with Appointment of Two New Independent Directors

      NEW YORK and BERLIN, May 23, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ:ATAI) ("atai" or "Company"), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced the appointment of Scott Braunstein, M.D., and Laurent Fischer, M.D., as independent directors of atai's supervisory board ("Board") subject to applicable legal requirements. Scott Braunstein, M.D., is the Chief Executive Officer ("CEO") and Chairman of Marinus Pharmaceuticals, Inc. He is an operating partner at Aisling Capital and serves on the Board of Directors at both Caribou Biosciences, Inc. and Trevena Inc. Previously, Dr. Braunstein was Chief Operati

      5/23/24 7:00:00 AM ET
      $ATAI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • atai Life Sciences Appoints Anne Johnson as Chief Financial Officer

      NEW YORK and BERLIN, Feb. 06, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ:ATAI) ("atai" or "Company") today announced that Anne Johnson, the Company's interim Chief Financial Officer since October 2023 and Chief Accounting Officer since August 2022, has been named Chief Financial Officer (CFO). Anne succeeds Stephen Bardin as the Company's CFO while Stephen will continue in an advisory role until March 31, 2024 to support the transition. "Anne has been an integral member of our team for over three years and has demonstrated the executive leadership, financial acumen, and track record to lead our financial organization with excellence," said atai Co-founder and Chief Executive Off

      2/6/24 5:00:31 PM ET
      $ATAI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ATAI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by ATAI Life Sciences N.V.

      SC 13D/A - ATAI Life Sciences N.V. (0001840904) (Filed by)

      9/27/24 7:56:26 PM ET
      $ATAI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by ATAI Life Sciences N.V. (Amendment)

      SC 13D/A - ATAI Life Sciences N.V. (0001840904) (Filed by)

      5/3/24 4:06:02 PM ET
      $ATAI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by ATAI Life Sciences N.V. (Amendment)

      SC 13D/A - ATAI Life Sciences N.V. (0001840904) (Filed by)

      3/12/24 9:30:31 PM ET
      $ATAI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ATAI
    Financials

    Live finance-specific insights

    See more
    • atai Life Sciences and Beckley Psytech Announce Positive Topline Results from the Phase 2b Study of BPL-003 in Patients with Treatment-Resistant Depression

      Study met its primary and all key secondary endpoints, and BPL-003 demonstrated rapid, robust and durable antidepressant effects with a single doseBoth 8 mg and 12 mg single doses of BPL-003 showed statistically significant and clinically meaningful reductions in depressive symptoms at all time points of the study compared to a 0.3 mg low-dose active control out to Week 8BPL-003 was generally well-tolerated at all doses, with 99% of treatment-emergent adverse events being mild or moderate, and no drug-related serious adverse events or suicide-related safety signalsMajority of patients deemed ready for discharge at the 90 minutes post-dose assessment, which suggests BPL-003 could fit within t

      7/1/25 6:00:00 AM ET
      $ATAI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • atai Life Sciences and Beckley Psytech to Combine Creating a Global Leader in Psychedelic Mental Health Therapies

      Strategic combination establishes a market-leading mental health company with a pipeline that includes potentially transformative, rapid-acting psychedelic assets differentiated by their convenient route of administration and short time-in-clinicCombined company will operate under the name atai Beckley with a joint leadership team and Board that leverage the deep psychedelic, drug development and CNS expertise within both organizationsTopline data from the Phase 2b study of BPL-003 in patients with treatment-resistant depression (TRD) is expected in mid-2025 - the largest controlled trial of mebufotenin (5-MeO-DMT) and the first and only controlled trial to investigate mebufotenin in the U.S

      6/2/25 6:00:00 AM ET
      $ATAI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • atai Life Sciences Announces Strategic Investment in Beckley Psytech to Accelerate the Clinical Development of Short-Duration Psychedelics

      Strategic investment in Beckley Psytech reinforces atai's position as the biopharmaceutical company with the largest and most diverse portfolio of clinical-stage psychedelic candidatesTwo patent-protected, clinical-stage programs BPL-003 (intranasal 5-MeO-DMT) and ELE-101 (intravenous psilocin) complement atai's existing drug development programs Multiple clinical readouts anticipated from this investment in Beckley Psytech within next 12 months, including a Phase 2b readout of BPL-003 in Treatment Resistant Depression in 2H24 BPL-003 has the potential to become a first-in-class short-duration psychedelic treatment with rapid acting and durable antidepressant effects Anticipated synergies th

      1/4/24 7:00:00 AM ET
      $ATAI
      Biotechnology: Pharmaceutical Preparations
      Health Care